Analysts have advised investors to buy Hero MotoCorp Ltd., Godrej Consumer Products Ltd. and United Spirits Ltd. among other stocks on Thursday.
Chandan Taparia, head of technical and derivatives research Motilal Oswal Financial Services Ltd., Swati Hotkar, AVP technical research, Nirmal Bang, Kush Bohra, founder, kushbohra.com and Nilesh Jain, head vice president technical and derivatives research, (Equity Research), Centrum Broking Ltd. shared their insights with NDTV Profit.
Hero MotoCorp
Taparia recommends purchasing the stock at Rs 3,940 with a target of Rs 4,210 and a stop loss of Rs 3,820. Over the past year, the stock has fallen 10.31%. Its relative strength index was at 54.30.
Out of 42 analysts tracking the company, 25 maintain a 'buy' rating, 10 recommend a 'hold' and seven suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 16.6%.
Godrej Consumer Products
Hotkar recommends purchasing the stock with a target of Rs 630 and a stop loss of Rs 570. Over the past year, the stock has risen 4.59%. Its relative strength index was at 70.45.
Out of 36 analysts tracking the company, 27 maintain a 'buy' rating, six recommend a 'hold' and three suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 2%.
United Spirits
Bohra recommends purchasing the stock, with a target of Rs 1,599 to Rs 1,625 and a stop loss of Rs 1,545. Over the past year, the stock has risen 33.60%. Its relative strength index was at 72.65.
Out of 25 analysts tracking the company, 16 maintain a 'buy' rating, four recommend a 'hold' and five suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies a downside of 1.6%.
Glenmark Pharmaceuticals
Taparia recommends purchasing the stock at Rs 1,412, with a target of Rs 1,475 and a stop loss of Rs 1,375. Over the past year, the stock has risen 31.89%. Its relative strength index was at 37.83.
Out of 12 analysts tracking the company, eight maintain a 'buy' rating, three recommend a 'hold' and one suggests 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 19.8%.
Torrent Pharmaceuticals
Jain recommends purchasing the stock with a target of Rs 3,420 and a stop loss of Rs 3,281. Over the past year, the stock has risen 24.04%. Its relative strength index was at 44.85.
Out of 33 analysts tracking the company, 19 maintain a 'buy' rating, nine recommend a 'hold' and five suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 7%.
Disclaimer: The views and opinions expressed by the investment advisers on NDTV Profit are of their own and not of NDTV Profit. NDTV Profit advises users to consult with their own financial or investment adviser before taking any investment decision.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
